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ABSTRACT: In an era of advanced diagnostics, metastasis to cervical
lymph nodes from an occult primary tumor is a rare clinical entity and
accounts for approximately 3% of head and neck malignancies.
Histologically, two thirds of cases are squamous cell carcinomas (SCCs),
with other tissue types less common in the neck. With modern imaging
and tissue examinations, a primary tumor initially undetected on physical
examination is revealed in >50% of patients and the site of the index
primary can be predicted with a high level of probability. In the present
review, the range and limitations of diagnostic procedures are
summarized and the optimal diagnostic workup is proposed. Initial
preferred diagnostic procedures are a fine-needle aspiration biopsy (FNAB)
and imaging. This allows directed surgical biopsy (such as tonsillectomy),
based on the preliminary findings, and prevents misinterpretation of
postsurgical images. When no primary lesion is suggested after imaging
and panendoscopy, and for patients without a history of smoking and
alcohol abuse, molecular profiling of an FNAB sample for human
papillomavirus (HPV) and/or Epstein–Barr virus (EBV) is important.
VC 2011 Wiley Periodicals, Inc. Head Neck 35: 123–132, 2013
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The term cancer of unknown primary (CUP) site repre-
sents a heterogeneous disease entity characterized by the
presence of lymphatic and/or hematogenous metastases
and an inability to identify the primary tumor. After thor-
ough diagnostic workup, including meticulous medical
history and clinical examination using modern diagnostic
tools, CUP accounts for approximately 3% of all patients
with cancer and 3% to 5% of those with solid tumors.1
Whether it is the small size, hidden location (eg, tonsillar
crypt), slow growth rate, or eventual involution of the pri-
mary tumor that hinders its recognition is speculative.2
Subsequent manifestation of the primary site occurs in
20% to 30% of cases.3
From a prognostic perspective, CUP can be categorized
into 2 groups comprising 4 major subtypes, as determined
by routine histopathological criteria (Table 1). The vast
majority of patients (80% to 90%) falls into the poor-risk
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CUP group and present with adenocarcinoma metastatic
to bone, brain, and/or viscera. Even with platinum-based
combination chemotherapy regimens, with or without
new generation cytotoxic drugs, complete responses are
seldom observed and median survival typically ranges
between 7 to 11 months.4,5 In the favorable prognostic
subset of 15% to 20% of patients with CUPs, the biologi-
cal behavior of the metastatic disease is similar to other
major known tumor types (ie, germ-cell tumors, adeno-
carcinoma of the breast or ovary, or squamous cell carci-
noma [SCC] of head and neck).
Metastatic cancer in cervical lymph nodes from an
unknown primary constitutes a favorable-risk CUP
group. Histologically, SCC accounts for 53% to 77% of
cases,6–8 particularly when masses are situated in the
upper two thirds of the neck, and generally indicates an
origin from a hidden primary somewhere in the head
and neck region. Tissue types other than SCC should
also be considered (ie, adenocarcinoma, undifferentiated
carcinoma, lymphoma, melanoma, papillary thyroid car-
cinoma, and central nervous system tumors).9,10 Metas-
tases to nodes in the lower neck often arise from cancer
below the clavicles, and are mainly adenocarcinomas.9
In the present review, current literature on CUP in cervi-
cal lymph nodes will be considered with an emphasis on
contemporary diagnostic procedures for primary tumor
identification, including molecular testing and positron-
emission tomography (PET) scanning. The discussion
will center on SCC, with brief mention of other histolog-
ical types.
Incidence and presentation
The proportion of patients in whom the primary tumor
is ultimately unknown reflects recent advances in imaging
and pathology, as well as the accuracy and extent of the
diagnostic workup. The reported incidence of metastatic
CUP in cervical lymph nodes of SCC histology ranges
from 1.5% to 9% of all head and neck malignancies.11–13
The wide range may be due to institutional variations in
diagnostic techniques and approaches implemented over
time. On reviewing the data of national registries, meta-
static SCC to cervical lymph nodes with unknown pri-
mary seems to account for no more than 3% of head and
neck malignancies. In a retrospective Danish national sur-
vey covering the period between 1975 and 1995, the an-
nual incidence of CUP metastatic to the cervical lymph
nodes with SCC histology was constant at 0.34 cases per
100,000/year, with the proportion in relation to total head
and neck cancers decreasing from 2.5% to 1.7% over the
same period.14 Whether the observed decline was due to
a more comprehensive initial diagnostic workup could
not be established from the retrospective data. According
to the National Cancer Registry of Slovenia, 125 SCC
cases were identified among 234 patients with cervical
lymph node metastases from a clinically undetectable pri-
mary in the period from 1975 to 1994. These cohorts rep-
resent 1.7% and 3.12%, respectively, of 7548 new
patients treated in Slovenia for head and neck malignan-
cies during the same time span.6,15
The typical patient with CUP metastatic to cervical
lymph nodes is male, 55 to 65 years old, with a history
of chronic tobacco and/or alcohol use.6,8,16,17 This pattern
is expected to change with an increase in younger non-
smokers presenting with human papillomavirus (HPV)-
related oropharyngeal cancer.18 Discrepancies observed in
some series may result from inclusion of patients with
tumors of other histological types (ie, undifferentiated
carcinomas, lymphomas, melanoma, and others).14,19–21
The symptom that usually prompts initial consultation is
a mass in the neck, and this accounted for 94% of the
352 patients in the series reported by Grau et al14 with
pain and weight loss only reported in 9% and 7%, respec-
tively. In a series of 167 patients reported by Issing et
al,8 the incidences of cervical "swelling,’’ pain, and dys-
phagia were 100%, 9%, and 3.6%, respectively. Typi-
cally, the enlarged cervical lymph nodes are located at
level II, followed by level III, with bilateral involvement
reported in <10%.6,8,14,16,17,22,23 The clinical N classifica-
tion in the majority of cases is N2a, N2b, and N2c, with
a median nodal size of 3.5 to 5 cm.6,14,16,17,23,24 The time
interval between the appearance of cervical mass and di-
agnosis ranges from 2 to 5 months.6,8,25
Diagnostic workup
The main objectives of the diagnostic evaluation of a
patient with CUP are: to determine the histology of the
metastatic tumor and to identify the primary tumor. These
2 objectives are interdependent because the results of the
first inform the search for the primary. Furthermore, the
diagnostic workup should determine the N and M classifi-
cation of the disease.
Tissue diagnosis
After a detailed office examination of the head and
neck and upper aerodigestive tract (UADT) with
TABLE 1. Cancer of unknown primary tumor: subset stratification
according to prognosis (adapted from References 1, 4, 5).
Group/tumor type Frequency Comment
Favorable prognosis 15% to 20% Treated according
to guidelines for
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nasopharyngoscopy, the initial tissue diagnostic procedure
is a fine-needle aspiration biopsy (FNAB). This is an effi-
cient, minimally invasive, and cost-effective diagnostic
method with negligible risk of seeding tumor cells along
the needle track.26 In comparison, core needle biopsy is
technically more demanding and less comfortable for the
patient, usually requires local anesthesia,27 and has poten-
tially more serious complications such as bleeding, infec-
tion, and fistula formation.26,27 FNAB results in a repre-
sentative cellular sample in the majority of patients. The
diagnosis is usually established with routine histologic
staining, supplemented by immunohistochemistry,26,28 and
with an experienced histopathologist, achieves a diagnostic
sensitivity of 83% to 97% and a specificity of 91% to
100% for metastatic lesions.26,29 Although image-guidance
technology has been shown to improve the efficacy of
fine-needle biopsies, particularly in an N0 neck, in patients
with a CUP the nodes will usually be palpable and image
guidance is of lesser importance. However, on-site assess-
ment of the aspirant (with repeated passage, if necessary)
and ultrasound-guidance are useful, particularly with large,
cystic nodes to direct the needle to the wall of the cystic
mass.26,28
In cystic metastases, a false-negative rate of 42% with
FNAB has been reported29 with sensitivities ranging from
33% to 50%,30 because it can be difficult to distinguish
cystic metastases from benign branchial (lymphoepithe-
lial) cysts. The differential diagnosis may also include an
abscess and tuberculosis.26,29–31 Excisional biopsy might
be needed to confirm malignancy but only after nondiag-
nostic image-guided FNAB and core biopsy. In a recent
report by Goldenberg et al,32 FNAB was found to be pos-
itive for malignant cells in 80% of cystic lymph node me-
tastases, confirming the efficacy of FNAB even with
cystic metastases. Ultrasound guidance of the FNAB ena-
bles the guidance of the needle to the relevant parts of
the neck mass (eg, the wall of a cystic lesion).
Open cervical lymph node biopsy is indicated only
when repeated FNABs followed by a core-needle biopsy
are nondiagnostic or in patients with masses clinically
and histologically suspicious for lymphoma.33 Even in
the latter situation, an ultrasound-guided cutting needle
biopsy is an alternative to the more invasive open bi-
opsy, with full subclassification of the disease possible
in 92% of malignant lymphoma cases.34 In 1944, Martin
and Morfit35 described open biopsy as "ill-advised and
needless surgery.’’ Increased rates of local complica-
tions, neck recurrence, and systemic dissemination have
also been reported by other authors after this proce-
dure.36,37 In contrast, no adverse effects in relation to
neck control or survival were reported in more recent
studies of open neck node biopsy, provided that biopsy
was followed by adequate definitive treatment, either in
the form of radiotherapy, comprehensive neck dissec-
tion, or both.38–40 In view of these data, it seems that it
is not imperative to perform an immediate subsequent
neck dissection when an open biopsy with frozen sec-
tions reveals metastatic cancer in the excised node. It
should be emphasized that an open neck node biopsy
should not be performed before a thorough clinical, radi-
ological, and endoscopic search for the primary tumor
has been completed.
The light microscopic examination of routine Giemsa
and Papanicolaou stained FNAB specimens (or the hema-
toxylin-eosin staining of tissue sections) allows for the
characterization of cell morphology and tumor differentia-
tion. In Papanicolaou-stained specimens, the orangeo-
phylic staining of cytoplasm of malignant cells is sugges-
tive (but not absolute proof) of SCC and its variants.41
Additional stains and, in particular, immunohistochemis-
try are subsequently used for the tissue diagnosis of un-
differentiated malignancies.42 An initial screening panel
using antibodies against a wide spectrum of cytokeratins,
common leukocyte antigen, carcinoembryonic antigen,
S100 protein, and desmin should differentiate carcinoma,
lymphoma, melanoma, and sarcoma. Vimentin can be
misleading, because it can be positive in spindle cell car-
cinomas that are cytokeratin negative.43 Further differen-
tiation can be achieved using antibodies against specific
cellular components, (ie, enzymes, structural tissue com-
ponents, hormones, and hormonal receptors; see below).
Identification of the primary tumor
The tonsillar fossa and the base of tongue are by far
the most common sites harboring an occult primary tumor
in patients presenting with metastatic SCC in cervical
lymph nodes and an unknown primary. In a series of 236
patients,33 almost 90% of all primaries were identified in
these 2 oropharyngeal subsites, which are notoriously
anatomically complex and difficult to assess. The
decreased likelihood of identifying the primary tumor in
other sites (eg, the nasopharynx or hypopharynx)
observed in recent series compared to earlier reports44 is
most likely the result of the availability of fiberoptic en-
doscopy and the advancement in CT and MRI technology.
A proper diagnostic evaluation identifies the primary tu-
mor in more than 50% of these patients overall,33,44 and
in two thirds of patients with suspicious findings on phys-
ical and/or radiological examinations, but only 30% of
patients without such findings.33
History and physical evaluation. These are the first steps in a
directed search for the occult primary. A history of exces-
sive alcohol consumption and heavy smoking may sug-
gest a primary tumor outside the nasopharynx, while a
history of multiple sexual partners and orogenital contact
may suggest a primary tumor within the oropharynx. An
accurate history of previous skin lesions (in particular
melanoma and SCC) with careful questioning of both the
patients and their physicians is important. Occasionally
the dermatologist or surgeon might not have sent an
excised skin lesion for histopathology.9
The location of cervical lymph node metastases may
suggest the location of the primary tumor.9,45 Tumors of
the lip and oral cavity usually metastasize to lymph nodes
in levels I to III, whereas metastases from oropharyngeal,
hypopharyngeal, laryngeal sites, and the thyroid tend to
appear lower in the jugular chain (levels II–IV) or cen-
trally in level VI. Approximately 50% of masses limited
to level IV and/or the supraclavicular fossa are from a
primary tumor arising below the clavicle (ie, the lung,
breast, gastrointestinal tract, kidney, and ovary). Cervical
lymph node metastases localized to level V are commonly
of nasopharyngeal or cutaneous origin. Enlarged parotid
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nodes should direct the search for a primary tumor of cu-
taneous or salivary origin. Bilateral cervical lymph node
metastases should focus attention on the nasopharynx,
base of tongue, hypopharynx, and midline structures.45
Information on hoarseness (vocal cords), dysphagia, or
referred pain (oropharynx or hypopharynx and supraglot-
tis) could also suggest the primary site.9 Sudden (over-
night) enlargement of a neck mass, particularly in non-
smokers and nondrinkers, at a rate beyond that which is
expected due to tumor cell proliferation should raise sus-
picion of an oropharyngeal malignancy, and especially if
cystic, of HPV-associated disease, or lymphoma.32 In the
series of Goldenberg et al,32 85% of 20 patients with
cystic metastases had primaries arising in palatine or lin-
gual tonsil, and the remaining 3 were CUP cases. Cystic
metastases should be considered in all patients with sus-
pected branchiogenic cysts who smoke and drink, espe-
cially if >40 years of age.46
A useful tip for clinical detection of the primary tumor
is to re-examine the patient looking for bleeding after the
initial palpation of the tonsil and tongue base, and retrac-
tion of the tonsillar pillars.
Lymphadenopathy elsewhere in the body is indicative
of a primary tumor outside the UADT, mainly lung,
breast, lower gastrointestinal tract, and lymphoma.9
Immunohistochemistry. A variety of antibodies directed
against specific components of the neoplasm can assist in
establishing the histological type of the metastasis and
hence, the most likely site of origin. A panel of immuno-
stains should be interpreted together with the morphologi-
cal characteristics and clinical presentation. The number
of antibodies used in the panel depends on the type/size
of specimen submitted for cytopathological or histopatho-
logical examination and the differential diagnosis after
initial cellular and immunohistochemical assessment.43
The diagnostic value of an immunohistochemical panel
of markers to determine the origin of the SCC metastatic
to cervical lymph nodes in 101 patients (with an other-
wise known primary) was studied by Park et al.47 Using
the classification and regression trees method, a combina-
tion of p16, cytokeratin 10, cytokeratin 19, and pRb cor-
rectly determined that 89.5% (34 of 38) cervical lymph
node metastases originating from an oropharyngeal pri-
mary, the frequency of classification was much lower for
other sites (oral cavity, 25%; hypopharynx, 30.8%; and
larynx, 57.1%).47
For adenocarcinomas, there are relatively specific tu-
mor markers that may help identify the site of the index
cancer: prostate, prostate-specific antigen and prostatic
acid phosphatase48 (Table 2); lung, thyroid transcription
factor-1 and cytokeratin 7þ/cytokeratin 2049,50; thyroid,
thyroid transcription factor-1 and thyroglobulin; breast,
gross cystic disease fluid protein 15, mammaglobin, and
estrogen receptors (ERs)51; colon, CDX2, cytokeratin
20þ/cytokeratin 752; pancreas/biliary, CDX2, cytokeratin
7þ/cytokeratin 20þ or cytokeratin 7þ/cytokeratin 2053;
ovary, ER, CA125, and mesothelin.54
Less common cancer types can also be characterized
using an appropriate panel of immunohistochemical
markers: germ cell tumors, placental alkaline phospha-
tase, OCT4, a-fetoprotein (AFP), human chorionic gonad-
otropin; hepatocellular carcinoma, Hepar 1, AFP, canalic-
ular pCEA/CD10/CD13; renal cell carcinoma (RCC) –
CD10; neuroendocrine carcinomas, chromogranin, synap-
tophysin, protein gene product 9.5.43 Detection of tumor
markers in needle washout fluid after the FNAB or in
fluid retrieved from cystic lesions is particularly useful
for characterization of thyroid lesions, where increased
thyroglobulin and calcitonin levels are highly indicative
of differentiated or the rarer medullary carcinoma,
respectively.
Imaging. Diagnostic imaging is aimed at assessing the
extent of cervical lymph node metastases, to identify the
index cancer, and to determine M classification. As men-
tioned previously, imaging should be performed before
any invasive diagnostic procedure, such as guided biop-
sies or tonsillectomy, in order to avoid false-positive
results or other misinterpretation due to tissue trauma,
and to assist with directing the tissue biopsies.
The mainstay of the imaging workup is contrast-
enhanced CT scan from the skull base to clavicles. It is
quick, has good spatial resolution, and is inexpensive. The
extent and location of cervical disease and its relationship
to neighboring structures, the presence of extracapsular
extension, the status of the retropharyngeal nodes, and con-
tralateral neck should be addressed. In the search for a pri-
mary tumor in the head and neck, a CT scan may be either
complemented or supplanted by an MRI with gadolinium
contrast, which has superior soft tissue resolution, particu-
larly for evaluation of nasopharynx or oropharynx. The
potential of a CT, MRI, or both to detect a primary tumor
TABLE 2. The main panels of immunohistochemical markers by tumor
type (adapted from Reference 43).
Tumor type Marker
Carcinoma Cytokeratins
Lymphoma CLA, ALK1, CD30, CD43
Melanoma S-100, HMB45, Melan-A
Sarcoma Vimetin, Actin, Desmin , MyoD1,
Myogenin, S100, CD34, CD99








Breast GCDFP-15, mammaglobin, ER
Colon CDX2, CK20þ/CK7
Pancreas/biliary CDX2, CK7þ/CK20þ or CK7þ/
CK20
Germ cell tumors PLAP, OCT4, AFP, HCG
Hepatocellular carcinoma Hepar 1, AFP
Renal cell carcinoma RCC, CD10
Neuroendocrine carcinoma Chromogranin, Synaptophysin,
PGP9.5
Abbreviations: CLA, common leukocyte antigen; ALK1, anaplastic lymphoma kinase; protein;
HMB45, anti-human melanosome; CK, cytokeratin; PSA, prostate-specific antigen; PAP, pros-
tatic acid phosphatase; TTF-1, thyroid transcription factor-1; GCDFP-15, cystic disease fluid
protein 15; ER, estrogen receptor; PLAP, placental alkaline phosphatase; OCT4 – Octamer-
binding transcription factor 4; AFP – a-fetoprotein; HCG – Human chorionic gonadotropin;
pCEA – Polyclonal carcinoembryonic antigen; PGP9.5 – Protein gene product 9.5.
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is in the range of 9.3% to 23%,7,13,55,56 rising to 60%
when suspicious radiologic findings direct subsequent en-
doscopic biopsies.33 Certain other examinations can be
obtained when a primary tumor is suspected to originate
from sites outside the head and neck (eg, a mammography
or MRI of the breast, or an octreotide scan for tumors of
neuroendocrine histology).
During the last 2 decades, F-18-fluorodeoxyglucose
(FDG) PET has been increasingly used in diagnostic algo-
rithms for CUPs and to evaluate the neck for residual dis-
ease after chemoradiotherapy. It has recently been supple-
mented by fusing functional information (FDG-PET) with
morphological data obtained by CT (FDG-PET/CT).
However, the resolution of FDG-PET limits its detection
capability to tumors 5 mm, and basal uptake of FDG in
normal lymphoid tissues of Waldeyer’s ring, and the
secretion of FDG from salivary glands may further limit
the identification of small and superficial lesions.
Several studies have evaluated the ability of PET/CT to
detect the primary tumor in patients with cervical lymph
node metastases of unknown origin. In a meta-analysis
conducted by Rusthoven et al57 (16 studies published
between 1994 and 2003, 302 patients), the detection rate
of the primary tumor was 24.5% (sensitivity 88.3%; spec-
ificity 74.9%; diagnostic accuracy 78.8%). Tonsils
accounted for the highest false-positive rate (39.3%)
while the lowest sensitivity rate was for the base of
tongue (80.5%).57 In a more recent meta-analysis for
hybrid FDG-PET/CT58 (11 studies published between
2005 and 2007, 433 patients), the primary tumor detection
rate was 37% (sensitivity and specificity 84%). The false-
positive rate (15%) was highest for oropharyngeal and
lung primaries.58 Analyzing another set of 8 studies from
2000 to 2009, in which FDG-PET or FDG-PET/CT was
used in 180 patients with cervical lymphadenopathy of
unknown origin, Al–Ibraheem et al59 reported a 28.3%
detection rate of primary tumors with 37% false-positive
scans. No analysis by tumor site or PET type was pro-
vided by the authors.59 In the past 2 years, 4 studies have
addressed this issue, and the results are in line with those
presented above.13,60–62 In 2 of these studies, the diagnos-
tic performances of whole-body FDG-PET and integrated
FDG-PET/CT were also compared and both indicated a
superiority of the latter. Thus, Waltonen et al13 reported
the following figures for FDG-PET (41 scans) and FDG-
PET/CT (52 scans): primary detection rate, 14.6% versus
44.2%; sensitivity, 42.9% versus 74.2%; specificity,
72.4% versus 72%; positive predictive value, 42.9% ver-
sus 76.7%; negative predictive value, 72.4% versus
69.2%; and accuracy, 55.1% versus 68.3%. Keller et al62
reported similar figures.
However, when attempting to assess the added value of
FDG-PET (with or without CT) to a conventional workup
in an unknown primary setting, one must be aware of
several obstacles and limitations related to studies already
published. As summarized by de Bree,63 the main issues
are the inclusion criteria (physical examination only vs
complete imaging and/or endoscopic workup with
directed biopsies), the definition of sensitivity (if the pos-
sibility of spontaneous regression of the primary is
ignored, all included patients and not only the sum of the
positive cases from all the different diagnostic techniques
should be used as a reference standard), and the standard-
ization of scanners and protocols which differ across the
studies, making the interpretation and comparison of
results difficult. The other potential drawbacks of PET
scanning are the high rate of false-positive findings, par-
ticularly if performed after a biopsy or in the orophar-
ynx,57,58 false-negative cases, the limited availability of
the procedure, the costs, the exposure to radiation, and
burden to the patient.63 Moreover, according to the Uni-
versity of Florida’s experience, a multivariate analysis for
primary tumor detection revealed that these studies had
no significant impact when weighted against other diag-
nostic procedures; however only 21 of the 236 patients
studied had FDG-PET or FDG-PET/CT.33 On the other
hand, the probability of a subsequent primary tumor
becoming apparent after a negative PET and panendo-
scopy is low (ie, less than 6%).64 Also, despite the rather
low primary detection rate, each patient in whom the pri-
mary tumor is correctly identified could benefit from less
extensive and, in some cases, more specific treatment
which should result in less morbidity for the patient.63 In
view of the above, a prospective, multicenter Dutch study
(PRIMUS) was conducted, in which patients without a
primary tumor detected after standard workup—including
physical examination, indirect laryngoscopy, and CT/
MRI—were directed to a blinded FDG-PET and panendo-
scopy with directed biopsies. During the same general an-
esthetic session, the results of the PET scan were pro-
vided to the surgeon for additional biopsies if still
required. Unfortunately, the results of this important study
are not yet available.63
Endoscopy with Biopsy. Definitive evaluation of the
unknown primary is panendoscopy of the UADT (phar-
yngoscopy including nasopharynx, laryngoscopy, and
esophagoscopy), with the patient under general anesthe-
sia, assisted by careful palpation of accessible regions,
and directed biopsies of clinically or radiologically suspi-
cious areas. Bronchoscopy is warranted when there is an
abnormality of the lung on chest imaging.9
The likelihood of discovering a primary tumor by en-
doscopy correlates with presence of suspicious findings
on preliminary examinations. When routine diagnostic
workup failed to identify a primary tumor, Cianchetti et
al33 found subsequent panendoscopy successful in 29.2%.
This figure doubled in patients with suspicious findings
present on any of the 2 examinations. A repeated panen-
doscopy is warranted only when the suspicious site was
not biopsied adequately during the first procedure.33,44
Although most hidden primaries are eventually identi-
fied in the tonsillar fossa and the base of tongue, given
the sensitivity of modern imaging modalities, random ton-
sillar biopsies and tonsillectomy are controversial.32 Also,
random sampling of normal appearing mucosa from naso-
pharynx and pyriform sinus may no longer be justified.
As a directed procedure, an ipsilateral tonsillectomy in
patients with lymphoid tonsil tissue is warranted and
yields an 18% to 44.6% primary tumor detection
rate,22,33,65–68 the wide range likely reflecting differences
in imaging. In the absence of a visible or palpable lesion,
Waltonen et al69 showed that tonsillectomy results in a
significantly higher likelihood of detecting an occult
CERVICAL LYMPH NODE METASTASES FROM CUP SITE: DIAGNOSTIC APPROACHES
HEAD &NECK—DOI 10.1002/HED JANUARY 2013 127
tonsillar tumor then a deep tonsil biopsy (29.5% versus
3.2%; p ¼ .0002). The evidence supporting bilateral ton-
sillectomy is less convincing, although rates of detection
of a primary in the contralateral tonsil of 10% (4 of 41)70
and 23% (5 of 22)71 have been reported.
It is possible that a formal lingual tonsillectomy may
have a higher yield than random mucosal biopsies of
base of tongue should a palatine tonsillectomy prove
unrevealing.
Molecular Studies. Better insight into etiology and pathoge-
nesis of head and neck tumors has led specific diagnostic
tests and effective therapeutic strategies. Molecular stud-
ies have the potential to improve diagnosis further.
Recently, a causal relationship between HPV, especially
type 16, and increased oropharyngeal SCC has been docu-
mented. Meta-analysis (Mehanna et al., unpublished data)
showed the overall prevalence of HPV in oropharyngeal
SCC was 47.7% (95% confidence interval, 42.9% to
52.5%) compared to 21.8% (95% confidence interval,
18.9% to 25.1%) for tumors at other head and neck sites.
In the oropharynx, prevalence of HPV has significantly
increased over the last decade in North America and
Europe; thus, the gap between these 2 regions that existed
before the year 2000 has now disappeared (69.8% versus
73.1%; p ¼ .8). Hence, there are strong arguments for
HPV testing all FNAB specimens from cervical lymph
nodes in CUP.
Begum et al72 used in situ hybridization for HPV16
testing on 77 consecutive aspirated cervical masses diag-
nosed as metastatic SCC. HPV16 was detected in 10 of
19 (53%) metastases from oropharyngeal and none from
nonoropharyngeal sites. To exclude possible bias due to
limited tumor sampling by FNAB, HPV16 status of the
primary oropharyngeal carcinomas was also determined:
in all but 1 case, HPV profiles were concordant. In the
same study, p16 expression (a surrogate HPV marker)
was also determined. The 2 markers were strongly associ-
ated, with p16 over-expression recorded in 12 of 13
HPV16-positive tumors and only 4 of 64 HPV16-negative
tumors (92% versus 6%; p < .0001).72 The same group
also assessed HPV16 status in surgically excised cervical
lymph node from 68 patients with SCC and found
HPV16 was only detected in oropharyngeal tumors.73
Similar findings have been reported by Zhang et al74 (in
FNAB samples) and by El–Mofty et al75 (in tissue sec-
tions), who also noted HPV-positivity is strongly associ-
ated with nonkeratinizing SCC.
Recently, Desai et al76 reported on the HPV status of
SCC metastatic to cervical lymph node from 41 patients
(37 tissue sections, 4 FNAB aspirates). Using a polymer-
ase chain reaction (PCR) with multiple primers, the HPV-
positivity rate was 44.4% in patients with oropharyngeal
primaries (4 of 9; all 3 cases with tonsillar tumors were
HPV-positive); 25% (8 of 32) for those with other tumor
sites, and 60% (3 of 5) for those where the primary tumor
remained unknown. No HPV-positive lesions were found
in the larynx or hypopharynx.76 The HPV16 status was
reported to be strongly associated with the presence of
cystic cervical lymph node metastases, which seems to be
a reliable marker of oropharyngeal origin: using in situ
hybridization, HPV DNA in tumor cells was confirmed in
13 of 15 cases with cystic lymph nodes (all with oropha-
ryngeal or an unknown primary) and in none of 21 cases
with solid lymph nodes (4 of 21 had an oropharyngeal
primary).32 Recently, HPV-associated nasopharyngeal
cancer has been reported in white North American
patients, thus indicating that the nasopharynx should
remain a potential site of origin in patients with HPV-
positive lymph nodes.77,78
Similarly, detection of Epstein–Barr virus (EBV) in an
involved cervical lymph node may suggest a nasopha-
ryngeal origin because this virus is implicated in the eti-
ology of undifferentiated nasopharyngeal tumors. EBV
assay should be considered in younger patients with
poorly differentiated SCC or undifferentiated carcinoma.
Using PCR, Feinmesser et al79 detected EBV genomes
in all 9 nasopharyngeal carcinomas (NPCs; 1 primary
lesion and 8 nodal metastases; tissue samples and fine-
needle aspirates were analyzed) but none of 20 lymph
nodes originating from other cancer types, 10 negative
lymph nodes, or 105 normal control samples. EBV was
found also in 2 additional patients with CUP and both
developed overt NPCs within 1 year.79 Conversely, only
1% of 300 primary tumor samples exclusive of NPC
were positive for EBV DNA in a North American
study.80
Although sensitivity and specificity rates close to 90%
have been reported for EBV in FNAB samples,81–84 the
sensitivity of PCR in nasopharyngeal biopsy tissue sam-
ples seems to be higher.83 Furthermore, in situ hybridiza-
tion for small EBV-encoded RNA is more sensitive and
specific than PCR in detecting EBV.85
The demonstration of EBV DNA in the plasma/serum
of patients with NPC has provided a new tool for NPC
detection and monitoring. Comparing genotypes of paired
samples from plasma and primary tumor, Lin et al86 have
found consistent similarity between both samples, sug-
gesting circulating cell-free EBV DNA may originate
from the primary tumor. The sensitivity and specificity of
using circulating EBV DNA for detection of NPC with
real-time PCR is 96% and 93%, respectively.87
Other methods for localizing the primary tumor
Several diagnostic methods are either under develop-
ment or too complex at the moment to be introduced into
daily practice. However, they may represent a clinically
useful tool in the search for the primary origin in the
future.
Micro RNA (miRNA) comprises approximately 22 nu-
cleotides – noncoding RNA molecules involved in regula-
tion of key cellular pathways associated with develop-
ment, differentiation, and tumorigenesis.88 As miRNA
seem to be a molecular fingerprint, Barker et al89
hypothesized that their expression profile, determined by
quantitative real-time PCR, could be predictive of the site
of metastatic disease. Analyzing matched-pairs of primary
tumor and metastatic cervical lymph node from 6 patients
with tonsillar, base of tongue, and nasopharyngeal tumors
the miRNA expression profile was consistent between the
primary site and nodal metastasis for individual patients
and between different patients within an individual ana-
tomic site (each primary site had a distinct miRNA
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expression profile). These results were confirmed by a
validation analysis conducted in a group of an additional
6 patients.89
Califano et al2 used microsatellite analysis to study the
genetic relationship between the directed biopsy samples
of clinically/histologically benign mucosa and the meta-
static tissue of cervical lymph nodes in 18 patients with
CUP to determine whether the site of origin could be
identified by molecular genetic means. A clinically de-
tectable primary tumor developed in 4 of the 10 cases
with at least 1 mucosal specimen that shared genetic
alterations with a cervical metastasis. In 3 of these, the
primary tumor had genetic changes identical to those in
the benign mucosal biopsy specimen and in the metastatic
cervical lymph node. In the fourth patient, no benign mu-
cosa sample was collected during the diagnostic proce-
dure from the site where the primary tumor subsequently
appeared.2
Image cytometry measures numerous nuclear features:
the foremost nuclear texture and organization on a 2-
dimensional snapshot of the chromatin structure could be
a surrogate marker for endpoint molecular genetic
changes in a nucleus.90 In a series of 21 patients, statisti-
cally significant differences between several nuclear mor-
phometric and textural features were found in the cellular
samples from cervical metastases obtained by FNAB
when patients were grouped according to the origin of
index cancer (oropharynx vs other sites).91
Finally, fluorescence-guided screening and diagnostic
evaluation of early neoplasia has also been used in CUP.
Kulapaditharom et al92 used laser-induced fluorescence
(LIF) endoscopy in parallel with a panendoscopy in 13
patients diagnosed with cervical metastasis and no visible
primary tumor. A primary tumor was disclosed with LIF
imaging and conventionally (after ipsilateral tonsillec-
tomy) in 5 (36.5%) and 2 (15.4%) patients, respectively,
whereas the LIF also effectively reduced the number of
unnecessary biopsies.90 Hayashi et al93 described the use
of narrow-band imaging in detection of the primary tumor
site in 46 patients with CUP with metastatic SCC in cer-
vical lymph nodes. After unsuccessful conventional diag-
nostic evaluation, including white-light endoscopy, 26
suspicious mucosal lesions in 25 patients were identified,
of which 16 lesions were histologically confirmed as
potential index SCC. All lesions were superficial neopla-
sia and located in hypopharynx (10 lesions) or orophar-
ynx (6 lesions).93 Recently, autofluorescent imaging
detected a clinically innocuous palatal tumor in a patient
previously treated for CUP.94
Assessment for distant metastases
Distant metastases at presentation are reported in 14%
of patients with cervical metastases from CUP.7 This crit-
ically impacts the treatment strategy and adversely affects
patient survival. A conventional diagnostic workup to
determine the M classification usually comprises a chest
CT scan and abdominal and pelvic ultrasound or CT. A
chest CT is useful in evaluating the mediastinum, and
especially valuable in cases with a higher risk of systemic
dissemination (level IV/V, N3, or bilateral nodal disease)
or when there is a strong suspicion of an index lung can-
cer (eg, positive thyroid transcription factor-1 staining of
the cervical node).50,95,96 Nevertheless, the low sensitivity
and specificity of a chest CT in detecting systemic metas-
tases (73% and 80%, respectively) indicates a need for a
more sensitive and whole-body screening technique.97
Other examinations (eg, skeletal scintigraphy and endos-
copies) are performed as clinically indicated, whereas
blood tests and abdominal CTs have only a low sensitiv-
ity for the detection of extrapulmonary disease.98,99
More recently, whole-body FDG-PET, with or without
CT integration, has been introduced for the M-staging of
head and neck cancer. Senft et al100 reported a prospec-
tive multicenter study with 145 consecutive patients with
head and neck cancer with an increased risk of distant
metastases, comparing chest CT and whole-body FDG-
PET for screening for distant metastases. With a sensitiv-
ity of 53% (vs 37%) and a positive predictive value of
80% (vs 75%), the superiority of PET scanning was con-
firmed over a conventional workup with CT, whereas the
combination of both modalities resulted in the highest
sensitivity (ie, 63%).100 No significant additional costs
were linked with more advanced screening procedures,
and with all 3 (CT, PET, PETþCT) found to be cost-
effective.101 Furthermore, assessing the interobserver vari-
ability in chest CT and whole-body FDG-PET screening
for distant metastases in patients with head and neck
SCC, higher kappa values for origin, susceptibility, and
overall conclusions were found for PET.102 These results
indicate that in clinical practice PET can be scored by 1
observer, but a CT should probably be scored by different
observers in consensus or combined with PET.102
FDG-PET and FDG-PET/CT were compared by Xu et
al103 who conducted a meta-analysis on 15 studies using
FDG-PET scanning in an initial systemic evaluation of
patients with head and neck cancer (FDG-PET, 7 studies
with 797 patients; FDG-PET/CT, 8 studies with 795
patients). The authors concluded that both examinations
have good diagnostic performance although FDG-PET/CT
tends to have higher diagnostic accuracy than FDG-
PET.103 Finally, a 3.0 Tesla whole-body MRI was
weighted against FDG-PET/CT scanning for assessment
of M-staging and distant-site synchronous primary tumors
in 150 patients with NPC.104 Both methods showed simi-
lar diagnostic performances with a sensitivity of 77.8%
versus 72.2% (p > .999), a specificity of 98.5% versus
97.7% (p > .999), and a diagnostic capability of 0.905
versus 0.878 (p ¼ .669). A combined interpretation of the
2 modalities demonstrated no significant benefit over the
sole use of either technique.104
CONCLUSION
Over the past several decades, substantial improvements
in diagnostics have allowed more accurate determination
of the extent of disease in the neck, systemic spread to
distant organs, and identification of the hidden primary
tumor in more than half the patients with CUP presenting
as a neck mass. In cases with no primary tumor on initial
investigations, the site of the index primary can be pre-
dicted with a high level of probability.
Supported by literature data, in an optimal scenario, the
diagnostic workup should be conducted in 4 steps. First,
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history, clinical examination with UADT assessed by
multiple examiners and modern imaging using contrast-
enhanced CT or MRI as a method of choice. The added
value of FDG-PET or FDG-PET/CT to conventional
workup has yet to be determined.
Second, tissue diagnosis is preferably obtained by a
FNAB; if the FNAB is nondiagnostic, it should be
repeated (image-guided). A core needle biopsy is indi-
cated after multiple inconclusive FNABs followed by
excisional biopsy of the enlarged node. Appropriate im-
munohistochemical studies allow tissue characterization
of tumor in the vast majority of patients.
Third, panendoscopy under general anesthesia with ip-
silateral tonsillectomy and directed biopsies. Optimal
imaging information of potential sites of the hidden pri-
mary tumor is crucial as this guides mucosal sampling.
Reversing the order of examinations increases the rate of
false positive findings on CT or PET. A second panendo-
scopy is indicated only when a suspicious mucosal site(s)
was inadequately biopsied during the previous procedure.
Fourth, molecular studies. For optimal predictive infor-
mation about a potential primary site, the HPV and/or
EBV immunostaining of the FNAB sample obtained from
the enlarged cervical lymph node is warranted, particu-
larly in cases where no suggestive findings are recorded
on imaging and panendoscopy and/or in patients without
a history of smoking and alcohol abuse.
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